Related Experiment Videos
Matrix metalloproteinases and processing of pro-TNF-alpha
A J Gearing1, P Beckett, M Christodoulou
1Neures Ltd., Abingdon, Oxon, UK.
Abstract:
Tumor necrosis factor-alpha (TNF-alpha) is released from a cell membrane-anchored precursor by proteolytic cleavage. We have shown that broad spectrum synthetic inhibitors of matrix metalloproteinases (MMPs) prevent the processing of the TNF precursor but do not inhibit the release of other cytokines. Purified MMPs, stromelysin, matrilysin, collagenase, and the gelatinases can all cleave a recombinant pro-TNF substrate to yield mature TNF. MMP inhibitors prevent the rise in blood levels of TNF after endotoxin administration in rats and are effective in animal models of inflammatory disease such as adjuvant arthritis. Drugs that inhibit MMP action and TNF release show great promise for the treatment of autoimmune inflammatory diseases.
Insights
Matrix metalloproteinases (MMPs) are crucial for releasing tumor necrosis factor-alpha (TNF-alpha). MMP inhibitors effectively block TNF-alpha release and show promise for treating inflammatory diseases.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Tumor necrosis factor-alpha (TNF-alpha) is a pro-inflammatory cytokine.
- TNF-alpha is produced from a membrane-bound precursor via proteolytic cleavage.
- Matrix metalloproteinases (MMPs) are implicated in this processing.
Purpose of the Study:
- To investigate the role of MMPs in TNF-alpha precursor processing.
- To evaluate the efficacy of MMP inhibitors in controlling TNF-alpha release and inflammatory conditions.
Main Methods:
- Utilized broad-spectrum synthetic MMP inhibitors.
- Tested purified MMPs (stromelysin, matrilysin, collagenase, gelatinases) on recombinant pro-TNF.
- Administered MMP inhibitors to rats challenged with endotoxin.
- Assessed MMP inhibitor efficacy in adjuvant arthritis models.
Main Results:
- Broad-spectrum MMP inhibitors prevented TNF-alpha precursor processing without affecting other cytokine release.
- Purified MMPs demonstrated the ability to cleave pro-TNF into mature TNF.
- MMP inhibitors successfully inhibited the rise in blood TNF levels post-endotoxin administration in rats.
- MMP inhibitors proved effective in animal models of inflammatory disease, including adjuvant arthritis.
Conclusions:
- MMPs are key enzymes responsible for the proteolytic cleavage of the TNF-alpha precursor.
- MMP inhibitors effectively block TNF-alpha release.
- Inhibiting MMPs and subsequent TNF-alpha release represents a promising therapeutic strategy for autoimmune inflammatory diseases.